Meet the 2020 Laureates: Christopher B. Newgard, PhD

Newgard.Christopher

Christopher B. Newgard, PhD

Outstanding Innovation Award

Christopher B. Newgard’s professional career has been devoted to metabolic research. Within the Sarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute (DMPI) where he is the director, he has developed a suite of comprehensive molecular profiling platforms across the “omics” sciences to support the work of his own laboratory and numerous others at Duke and outside institutions. In particular, he leverages these platforms to gain deeper understanding of dysregulated metabolic function in cardiometabolic diseases, including obesity, diabetes, cardiovascular diseases, and kidney diseases.

Indeed, Dr. Newgard has developed one of the most active and collaborative metabolomics laboratories in the world and has used these tools for defining mechanisms underlying pandemic metabolic disorders. For example, he has shown that a cluster of metabolites from the branched‐chain amino acid (BCAA) catabolic pathway is more strongly associated with insulin resistance than other metabolite clusters, including lipid‐related clusters, in humans; and in animal studies, BCAA supplementation exacerbates insulin resistance, whereas BCAA restriction improves insulin action. Remarkably, the BCAA‐related metabolite cluster is predictive of diabetes intervention outcomes at baseline, and strongly responsive to such interventions. Moreover, the BCAA‐related signature is influenced by the gut microbiome and may also contribute to obesity‐associated behavioral abnormalities.

Dr. Newgard has developed one of the most active and collaborative metabolomics laboratories in the world and has used these tools for defining mechanisms underlying pandemic metabolic disorders.

Furthermore, he has a major interest and an extensive track record in research on pancreatic islet biology. Using differentially glucose‐responsive insulinoma cell lines created in the Newgard laboratory, NMR‐based analysis was applied to demonstrate that glucose‐stimulated insulin secretion (GSIS) is tightly correlated to pyruvate anaplerosis and cycling activity rather than pyruvate oxidation. He subsequently demonstrated that a pyruvate/isocitrate/glutathione pathway is a potent regulator of GSIS, and that intermediates in this novel pathway are able to rescue function in glucose unresponsive islets from humans with type 2 diabetes. Dr. Newgard has also demonstrated that overexpression of the homeobox transcription factor Nkx6.1 in pancreatic islets simultaneously enhances GSIS and β‐cell replication. This rare dual effect has led the group to explore the pathways activated by Nkx6.1. Nkx6.1 enhances GSIS by induction of a prohormone, VGF, which is processed to yield multiple peptides, including TLQP‐21, which is insulinotropic, protective against apoptotic agents, and able to attenuate onset of hyperglycemia in a rat model of type 2 diabetes.

You may also like

  • Hoshino Wins Wayne Bardin International Travel Award

    The Endocrine Society has selected Yoshitomo Hoshino, MD, PhD, as the recipient of its 2025 C. Wayne Bardin, MD, International Travel Award for his outstanding ENDO abstract and research contributions to the care of patients with bone health disorders. The C. Wayne Bardin, MD, International Travel Award was created in honor of Past President Wayne…

  • Webinar Will Examine Concerns Around Compounding Anti-Obesity Medications

    Endocrine Society to host virtual Science Writers Conference Nov. 14 Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications. Endocrine Society experts will discuss the importance of prescribing FDA-approved medications to treat obesity during the Society’s Virtual Science Writers Conference on November 14. What:…

Find more in